Clinical Trial Update: Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating vorasidenib in combination with pembrolizumab for recurrent or progressive IDH-1 mutant gliomas (astrocytoma and oligodendroglioma); th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma
• Oligodendroglioma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Vorasidenib (vorasidenib)

Snippet

Sponsor: Institut de Recherches Internationales Servier | Conditions: Astrocytoma, Oligodendroglioma | Phase 1 | Status: ACTIVE_NOT_RECRUITING